Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewCarbenoxolone disodium is a glucocorticoid that inhibits 11β-hydroxysteroid dehydrogenase (11-HSD) and blocks gap junction communication.
M. Wt | 614.72 |
Formula | C34H48Na2O7 |
Storage | Store at +4°C |
Purity | ≥98% (HPLC) |
CAS Number | 7421-40-1 |
PubChem ID | 636402 |
InChI Key | BQENDLAVTKRQMS-SBBGFIFASA-L |
Smiles | [Na+].[Na+].[H][C@@]12C[C@](C)(CC[C@]1(C)CC[C@]1(C)C2=CC(=O)[C@]2([H])[C@@]3(C)CC[C@H](OC(=O)CCC([O-])=O)C(C)(C)[C@]3([H])CC[C@@]12C)C([O-])=O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
water | 61.47 | 100 |
The following data is based on the product molecular weight 614.72. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.63 mL | 8.13 mL | 16.27 mL |
5 mM | 0.33 mL | 1.63 mL | 3.25 mL |
10 mM | 0.16 mL | 0.81 mL | 1.63 mL |
50 mM | 0.03 mL | 0.16 mL | 0.33 mL |
References are publications that support the biological activity of the product.
Jellinck et al (1993) Differential inhibition of 11 beta-hydroxysteroid dehydrogenase by carbenoxolone in rat brain regions and peripheral tissues. J.Steroid Biochem.Mol.Biol. 46 209 PMID: 8664169
Sagar and Larson (2006) Carbenoxolone inhibits junctional trasnfer and upregulates connexin43 expression by a protein kinase A-dependent pathway. J.Cell.Biochem. 98 1543 PMID: 16552723
If you know of a relevant reference for Carbenoxolone disodium, please let us know.
Keywords: Carbenoxolone disodium, Carbenoxolone disodium supplier, Gap, junction, blockers, inhibitors, inhibits, 11, β-hydroxysteroid, beta-hydroxysteroid, dehydrogenase, gap, Connexins, Channels, Dehydrogenases, 11b-Hydroxysteroid, Dehydrogenase, 3096, Tocris Bioscience
Citations are publications that use Tocris products. Selected citations for Carbenoxolone disodium include:
Craig and Martin (2012) Dominance of flow-mediated constriction over flow-mediated dilatation in the rat carotid artery. Br J Pharmacol 167 527 PMID: 22537086
Shuhaibar et al (2015) Intercellular signaling via cyclic GMP diffusion through gap junctions restarts meiosis in mouse ovarian follicles. Proc Natl Acad Sci U S A 112 5527 PMID: 25775542
Chai et al (2017) Neural Circuit-Specialized Astrocytes: Transcriptomic, Proteomic, Morphological, and Functional Evidence. Neuron 95 531 PMID: 28712653
Ferlauto et al (2018) Design and validation of a foldable and photovoltaic wide-field epiretinal prosthesis. Nat Commun 9 992 PMID: 29520006
Bhaskaracharya et al (2014) Probenecid blocks human P2X7 receptor-induced dye uptake via a pannexin-1 independent mechanism. PLoS One 9 e93058 PMID: 24671093
Do you know of a great paper that uses Carbenoxolone disodium from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review Carbenoxolone disodium and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.